Segmentectomy vs Lobectomy for 2 - 3cm IASLC Grade 1-2 Lung Adenocarcinoma: A Multi-center RCT

NCT ID: NCT07169903

Last Updated: 2025-09-12

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 587 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-10-01
• Study Completion Date: 2033-12-31

Brief Summary

This study is a prospective, multicenter randomized controlled trial (RCT) designed to compare the efficacy of segmentectomy and lobectomy for invasive lung adenocarcinoma with a diameter of 2-3 cm and intraoperative frozen section-confirmed IASLC pathological new grade 1-2. The non-inferiority of segmentectomy is primarily evaluated by 5-year relapse-free survival (RFS) and overall survival (OS) after surgery, while secondary endpoints include pulmonary function preservation, perioperative complications, etc. With a planned enrollment of 587 patients over a 3-year recruitment period and a 5-year follow-up, this study aims to identify an optimized surgical approach.

Detailed Description

Lung cancer is the most prevalent and lethal malignant tumor worldwide. Surgical resection remains the most effective treatment for early-stage lung cancer, with lobectomy historically serving as the standard procedure. Recent studies have demonstrated that segmentectomy can achieve comparable outcomes to lobectomy for tumors ≤2 cm and those with ground-glass opacity dominance (CTR ≤0.5). However, for invasive lung adenocarcinomas measuring 2-3 cm with solid predominance (CTR >0.5), high-level evidence supporting segmentectomy as an alternative to lobectomy is lacking. The 2020 International Association for the Study of Lung Cancer (IASLC) proposed a new grading system for invasive adenocarcinoma, which stratifies prognosis based on histologic subtypes. Tumors with IASLC Grade 1-2 (≤20% high-grade components) have better outcomes, but their optimal surgical approach (segmentectomy vs. lobectomy) in solid-predominant lesions (2-3 cm) remains unproven. Intraoperative frozen section has shown high accuracy in diagnosing IASLC grades, enabling real-time surgical decision-making. The primary objective of this study is to evaluate whether segmentectomy is non-inferior to lobectomy in terms of 5-year relapse-free survival (RFS) and overall survival (OS) for patients with 2-3 cm lung adenocarcinomas confirmed as IASLC Grade 1-2 by intraoperative frozen section.

Conditions

Lung Adenocarcinoma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Lobectomy Group

Lobectomy includes resection of the right upper or lower lobe, and the left upper or lower lobe. Resection of more than one pulmonary lobe does not meet the criteria. The surgical margin, that is, the distance between the cut end covered by the visceral pleura and the tumor edge, is evaluated macroscopically to confirm that the surgical margin is not less than the maximum diameter of the tumor or 20 mm. If there is no frozen pathological diagnosis or cytological examination, it is necessary to confirm that there is no tumor residue at the margin before closing the chest. If the resection margin is positive for residual tumor cells, further surgical resection beyond the planned procedure must be performed.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Segmentectomy group

Segmentectomy involves resection of a pulmonary segment or a segment along with its adjacent segments. After segmentectomy, the surgical margin is examined macroscopically by evaluating the distance between the cut end covered by the visceral pleura and the tumor edge. If the surgical margin is smaller than the maximum diameter of the tumor or 20 mm, or if the margin is positive for residual tumor cells, the resection scope should be expanded. If the margin remains positive after expansion, segmentectomy should be converted to lobectomy.

Group Type: EXPERIMENTAL

Pulmonary segmentectomy

Intervention Type: PROCEDURE

Segmentectomy is applied to lung adenocarcinomas with a diameter of 2-3 cm, in which intraoperative frozen pathology confirms a new pathological grade of 1-2.

Interventions

Pulmonary segmentectomy

Segmentectomy is applied to lung adenocarcinomas with a diameter of 2-3 cm, in which intraoperative frozen pathology confirms a new pathological grade of 1-2.

Intervention Type: PROCEDURE

Other Intervention Names

Segmentectomy

Eligibility Criteria

Inclusion Criteria

• Suspicion of non-small cell lung cancer (NSCLC).

• Solitary nodule or concomitant lesions with microinvasion or below.

• Primary tumor not located in the middle lobe.

• No suspected lymph node involvement. 3. Preoperative CT lung window (window level -700HU, window width 1500HU) indicates the nodule is predominantly solid, i.e., the consolidation-to-tumor ratio (CTR) is greater than 0.5 (CTR > 0.5).

4. Good lung function (FEV1 > 1.5 L or FEV1% ≥ 60%), tolerable for both segmentectomy and lobectomy.

5. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2. 6. Voluntary participation with signed informed consent, able to comply with study visit plans and other protocol requirements.

7. No history of ipsilateral thoracotomy; video-thoracoscopic examination meets the criteria.

8. No history of chemotherapy or radiotherapy, including treatment for other cancers. Eligible if more than 5 years have passed since completion of perioperative adjuvant chemotherapy. Eligible if there is a history of or ongoing hormone therapy.

9. All the following laboratory test results are eligible (all laboratory tests use the latest results within 28 days before initial registration; laboratory tests on the same day within 4 weeks before initial registration are allowed):

• White blood cell count ≥ 3000/mm³.
• Hemoglobin ≥ 8.0 g/dL (without blood transfusion within 28 days before initial registration).

• Platelet count ≥ 10×10⁴/mm³.

• AST ≤ 100 IU/L.

⑤ ALT ≤ 100 IU/L.

⑥ Total bilirubin ≤ 2.0 mg/dL.

2. Intraoperative frozen section shows negative surgical margins. 3. Intraoperative exploration reveals no severe adhesions or lymph node inflammatory changes (adhesions of pulmonary vessels or bronchi), confirming feasibility for both lobectomy and segmentectomy.

Exclusion Criteria

1. Active bacterial or fungal infection (confirmed by imaging diagnosis or bacteriological examination with fever >38°C).

2. Multiple active cancers (synchronous or metachronous multiple primary cancers, excluding in situ carcinoma or intramucosal cancer lesions considered cured by local treatment; such lesions are not included in active multiple cancers).

3. Patients with severe impairment of cardiac, hepatic, or renal function (cardiac function grade 3-4; ALT and/or AST more than 3 times the upper limit of normal; Cr exceeding the upper limit of normal).

4. Patients with concomitant other malignant tumors or hematological diseases.

5. Pregnant, planning to become pregnant, or lactating female patients (diagnosed with early pregnancy when urine HCG >2500 IU/L).

6. Any form of antitumor therapy before tumor resection, including interventional chemotherapy embolization, ablation, radiotherapy, chemotherapy, and molecular targeted therapy.

7. Patients who participated in other tumor-related clinical trials within the past three months.

8. Preoperative CT suggests ground-glass predominant nodules (CTR < 0.5).

9. Patients with positive lymph nodes indicated by preoperative imaging or lymph node puncture (clinical N stage = 1 or 2).

10. Patients with tumors near the hilum who cannot undergo segmentectomy.

11. Patients deemed unsuitable for enrollment by the investigator.

1. Patients with IASLC grade 3 (≥20% pathological high-grade subtypes) indicated by intraoperative frozen section.

2. Patients confirmed with in situ carcinoma or microinvasive adenocarcinoma by intraoperative frozen section.

3. Patients with preoperative findings of distant metastasis or pleural/ascitic effusion.

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 79 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

Sponsor Role: collaborator

Affiliated Hospital of Nantong University

OTHER

Sponsor Role: collaborator

Huadong Hospital

OTHER

Sponsor Role: collaborator

Anhui Chest Hospital

OTHER

Sponsor Role: collaborator

Ningbo No. 1 Hospital

OTHER

Sponsor Role: collaborator

Ningbo No.2 Hospital

OTHER

Sponsor Role: collaborator

Center hospital of Nanyang

UNKNOWN

Sponsor Role: collaborator

The Affiliated Hospital of Xuzhou Medical University

OTHER

Sponsor Role: collaborator

Huzhou Central Hospital

OTHER

Sponsor Role: collaborator

Anhui Provincial Hospital

OTHER_GOV

Sponsor Role: collaborator

Shandong Public Health Clinical Center

OTHER_GOV

Sponsor Role: collaborator

Shanghai Pulmonary Hospital, Shanghai, China

OTHER

Sponsor Role: lead

Responsible Party

Chang Chen

Professor at Tongji University School of Medicine and Chief Physician of the Department of Thoracic Surgery at Shanghai Pulmonary Hospital

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Shanghai Pulmonary Hospital

Shanghai, Shanghai Municipality, China

Countries

China

Central Contacts

Haojie Si, MD

Role: CONTACT

2446135063@qq.com

+8613777120014

Facility Contacts

Chang Chen, PhD, MD

Role: primary

chenthoracic@163.com

+8613816869003

Other Identifiers

STAR012

Identifier Type: -

Identifier Source: org_study_id